Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hinokitiol SCHEMBL4653999 | 0.83 | TP53 (0.70) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| SCHEMBL23250676 | 0.79 | GABRA1 (0.54) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| SCHEMBL6546310 | 0.78 | GABRA1 (0.48) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL2414429 | 0.78 | GABRA1 (1.00) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL36245 | 0.78 | GABRA1 (1.00) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL8935177 | 0.75 | GABRA1 (0.94) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL5036811 | 0.75 | GABRA1 (0.94) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL10968613 | 0.75 | GABRA1 (0.94) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL4088686 | 0.75 | GABRA1 (0.94) | GABRA1GABRB2CYP1A2HIF1AGABRB1 | |
| Propofol SCHEMBL1033835 | 0.75 | GABRA1 (0.94) | GABRA1GABRB2CYP1A2HIF1AGABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-113759026-B | Common clubmoss herb and preparation characteristic map and construction method thereof | 北京康仁堂药业有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-2874664-B1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX | CENTRE EUGENE MARQUIS (FR) | 2019-06-19 | — | — | EP | claimed |
| US-9572770-B2 | Stable topical composition and a process for producing a stable topical composition | EVIDENCE SOLUCÕES FARMACÊUTICAS LTDA EPP (BR) | 2017-02-21 | — | — | US | claimed |
| EP-2874664-A1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE- EARTH RADIOISOTOPE COMPLEX | Centre Eugene Marquis (FR) | 2015-05-27 | — | — | EP | claimed |
| WO-2014012997-A1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE- EARTH RADIOISOTOPE COMPLEX | CENTRE EUGENE MARQUIS (FR) | 2014-01-23 | — | — | WO | claimed |
| US-20130123220-A1 | Stable Topical Composition and a Process for Producing a Stable Topical Composition | EVIDENCE SOLUÇÕES FARMACÊUTICAS LTDA EPP (BR) | 2013-05-16 | — | — | US | claimed |
| WO-2012009778-A2 | A STABLE TOPICAL COMPOSITION AND A PROCESS FOR PRODUCING A STABLE TOPICAL COMPOSITION | EVIDENCE SOLUÇÕES FARMACÊUTICAS LTDA EPP (BR) | 2012-01-26 | — | — | WO | claimed |
| EP-4735568-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | The Procter & Gamble Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735567-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | The Procter & Gamble Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| WO-1997047289-A1 | STABILIZED HINOKITIOL AND COMPOSITIONS CONTAINING SAME | E-L MANAGEMENT CORPORATION (US) | 1997-12-18 | — | — | WO | disclosed |
| CN-1008325-B | ORAL COMPOSITION | LION CORP (JP) | 1990-06-13 | — | — | CN | disclosed |
| EP-0108622-B1 | SYNTHETIC RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI RAYON CO., LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
| CN-85109275-A | ORAL COMPOSITION | — | 1986-06-10 | — | — | CN | disclosed |
| US-4563494-A | LANTHANOID COMPOUND | MITSUBISHI RAYON CO., LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | GABRA1 4231/4885GABRB2 2535/4885CYP1A2 3865/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | GABRA1 3154/4885GABRB2 3862/4885CYP1A2 3978/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | GABRA1 1529/4885GABRB2 1395/4885CYP1A2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.